Xie L-D, Gao Y, Li M-R, Lu G-Z, Guo X-H
Department of Endocrinology, Peking University First Hospital, Beijing, China.
Clin Exp Immunol. 2008 Nov;154(2):172-6. doi: 10.1111/j.1365-2249.2008.03756.x. Epub 2008 Sep 5.
The mechanism of disease progression in Hashimoto's thyroiditis (HT) is still unclear. Anti-thyroid peroxidase antibody (TPOAb), a diagnostic hallmark of HT, is principally of the immunoglobulin G (IgG) isotype, and it appears to be a response to thyroid injury. The aim of our study was to evaluate the distribution of IgG subclasses of TPOAb in sera from patients with HT with different thyroid functional status. Sera from 168 patients with newly diagnosed HT were collected and divided into three groups according to thyroid function: patients with hypothyroidism (n = 66), subclinical hypothyroidism (n = 60) and euthyroidism (n = 42). Antigen-specific enzyme-linked immunosorbent assay was used to detect the distribution of TPOAb IgG subclasses. The prevalence of TPOAb IgG subclasses in all patients' sera with HT was IgG1 70.2%, IgG2 35.1%, IgG3 19.6% and IgG4 66.1% respectively. The prevalence of IgG2 in sera from patients with hypothyroidism (51.5%) was significantly higher than that of subclinical hypothyroidism (33.3%) (P < 0.05), and the latter was also significantly higher than that of euthyroidism (11.9%) (P < 0.05). The positive percentage of IgG2 subclass in sera from patients with hypothyroidism and subclinical hypothyroidism was significantly higher than that of euthyroidism (P < 0.05), the prevalence and positive percentage of IgG4 subclass in sera from patients with hypothyroidism and subclinical hypothyroidism was significantly higher than that of euthyroidism respectively (P < 0.05). The predominant TPOAb IgG subclasses in sera from patients with HT were IgG1 and IgG4. Patients with high levels of TPOAb IgG2, IgG4 subclasses might be at high risk of developing overt hypothyroidism.
桥本甲状腺炎(HT)的疾病进展机制仍不清楚。抗甲状腺过氧化物酶抗体(TPOAb)是HT的诊断标志,主要为免疫球蛋白G(IgG)同种型,它似乎是对甲状腺损伤的一种反应。我们研究的目的是评估不同甲状腺功能状态的HT患者血清中TPOAb的IgG亚类分布。收集了168例新诊断HT患者的血清,并根据甲状腺功能分为三组:甲状腺功能减退患者(n = 66)、亚临床甲状腺功能减退患者(n = 60)和甲状腺功能正常患者(n = 42)。采用抗原特异性酶联免疫吸附试验检测TPOAb IgG亚类的分布。所有HT患者血清中TPOAb IgG亚类的患病率分别为IgG1 70.2%、IgG2 35.1%、IgG3 19.6%和IgG4 66.1%。甲状腺功能减退患者血清中IgG2的患病率(51.5%)显著高于亚临床甲状腺功能减退患者(33.3%)(P < 0.05),后者也显著高于甲状腺功能正常患者(11.9%)(P < 0.05)。甲状腺功能减退和亚临床甲状腺功能减退患者血清中IgG2亚类的阳性百分比显著高于甲状腺功能正常患者(P < 0.05),甲状腺功能减退和亚临床甲状腺功能减退患者血清中IgG4亚类的患病率和阳性百分比分别显著高于甲状腺功能正常患者(P < 0.05)。HT患者血清中主要的TPOAb IgG亚类是IgG1和IgG4。TPOAb IgG2、IgG4亚类水平高的患者可能有发生明显甲状腺功能减退的高风险。